CV Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting third-quarter net product sales of $3,028 thousand and a net loss of $93 thousand.

Key Highlights

  • Quarterly net sales: Product sales, net were $3,028 thousand for the three months ended September 30, 2026, compared to $3,256 thousand in the same period of 2025, according to the filing.
  • Quarterly net loss: The company reported a net loss of $93 thousand for Q3 2026, versus a net loss of $382 thousand in Q3 2025.
  • Nine-month net loss: For the nine months ended September 30, 2026, net loss totaled $1,511 thousand, compared to $752 thousand in the prior-year period.
  • Legal settlement gain: The company recorded a gain on legal settlement of $500 thousand in the third quarter of 2026, as disclosed in Note 9 of the filing.
  • Share count increase: Common shares issued and outstanding rose to 235,694 thousand as of September 30, 2026, from 184,264 thousand as of December 31, 2025, primarily through note conversions.
  • Total assets: Total assets were $6,434 thousand at September 30, 2026, down from $6,962 thousand at December 31, 2025.
  • Accumulated deficit: The accumulated deficit stood at $89,450 thousand as of September 30, 2026, compared to $87,939 thousand at December 31, 2025.

CV Sciences Q3 2026 Financial Results: Sales, Losses, and Debt Conversions

CV Sciences, Inc. (OTC:CVSI), a San Diego-based company that sells CBD consumer products, reported condensed consolidated financial results for the three and nine months ended September 30, 2026 in its quarterly filing. Net product sales for the third quarter reached $3,028 thousand, down from $3,256 thousand in Q3 2025, while gross profit was $3,028 thousand on cost of goods sold of $1,514 thousand, yielding a gross profit of $1,514 thousand. Total operating expenses for the quarter were reduced to $1,137 thousand, partly because of the $500 thousand gain on legal settlement, contributing to operating income of $377 thousand for the period.

Despite the operating income, the company reported a net loss of $93 thousand for Q3 2026, driven by $470 thousand in total other expense. This other expense category included a $263 thousand loss on debt conversions and a $207 thousand change in fair value of convertible notes, both of which the filing attributes to convertible note activity during the quarter. For the nine months ended September 30, 2026, cumulative losses on debt conversions totaled $512 thousand and the change in fair value of convertible notes totaled $678 thousand, the filing disclosed.

Common shares outstanding expanded from 184,264 thousand at December 31, 2025 to 235,694 thousand at September 30, 2026, as the company issued shares through note conversions totaling 51,430 thousand shares across three quarters. The company had $308 thousand in cash, total stockholders' equity of $2,273 thousand, and convertible notes carried at fair value of $741 thousand as current liabilities at the end of the quarter. The filing states the company had 242,184,128 shares of issued and outstanding common stock as of November 5, 2026.

What Was Disclosed

CV Sciences filed a 10-Q for the quarter ended September 30, 2026, disclosing a $93 thousand net loss on $3,028 thousand in net product sales, a $500 thousand legal settlement gain, significant share issuances from note conversions, and total assets of $6,434 thousand.